USFDA grants EIR to Dishman Pharma

Dishman Pharmaceuticals and Chemicals, which specialises in manufacturing active ingredients, informed that it has received an establishment inspection report (EIR) from US food and drug administration (USFDA). 

The company has received the EIR from USFDA for its Bavla facility in Gujarat on February 01, which was inspected by the USFDA in July, 2016. Therefore, the plants in Naroda, Bavla and Switzerland continue to remain approved by the US FDA. 

The stock of the company on February 1, 2017 ended in green with the gains of 0.77 per cent. However, the sector still remains under pressure as the new elected US President Donald Trumps' agenda towards the pharma industry is not in-line with the industry estimates. However, in the last one year, the stock of the company has surged by 37.04 per cent. 

The share price of Dishman Pharmaceuticals and Chemicals gained 4.5 percent intraday on Thursday.